Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-CP23
- Development stage
- Unknown
- Lead developer
- GlycosBio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GB-CP23 (also known as GB-AOS6) is an investigational adjunctive therapy being developed by GlycosBio for the treatment of Group A Streptococcus-associated clinical pharyngitis (strep throat). It utilizes GlycosBio's proprietary Activated Oil System (AOS) platform, which consists of engineered lipids designed to selectively target bacterial pathogens while preserving commensal microbiota. GB-CP23 is administered as an adjunctive treatment alongside standard-of-care antibiotics. It has been evaluated in a Phase 1 clinical trial (known as 'The Lion Trial') to assess its safety, tolerability, and exploratory efficacy in children and adolescents with sore throats.
Beyond the preview
Go deeper on GB-CP23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-CP23.